Abstract

FORMULATION AND EVALUATION OF EXTENDED RELEASE MATRIX TABLETS OF DESVENLAFAXINE SUCCINATE

Gajanan Jalindar Chavan*, Sachin Dhondiram Patil, Atul Pandurang Kumbhar, Nikhil Prabhakar Patil, Swapnali Roshan Charya, Rohit Bhaskar Kadam

Abstract

The objective of this investigation was to prepare extended release of Desvenlafaxine succinate and to carryout in-vitro dissolution studies to demonstrate sustained action of designed dosage form. The design of dosage form was performed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K4M), Carbopol (Acrypol 974), Microcrystalline cellulose (MCC) polymers as matrix builders and Polyvinyl pyrolidone (Kollidon K30) as granulating polymer. Granules were prepared by mixing thoroughly HPMC K4M, Carbopol (Acrypol 974P) and Microcrystalline cellulose with the drug and then by kneading with granulating solution of Polyvinyl pyrrolidone with Isopropyl alcohol & air dried. Optimized formulation of 100 mg Desvenlafaxine was formed by using 33.78 % HPMC K4M, 3% Microcrystalline cellulose, 15% of Carbopol (Acrypol 974) and 5% ratio of Kollidon K30 as binder .The network formed by HPMC, MCC and Carbopol (Acrypol 974) in the granules when compacted by compressing it into a Tablet exhibited 24 hours extended drug release in vitro.

Keywords: Desvenlafaxine Succinate SR Matrix Tablet, DVS, HPMC K4M, Carbopol, Extended release.